An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors

• Published in: Case reports in oncological medicine 2019, Vol.2019 (2019), p.1-7
• Main Authors: Chiu, Edwin, Tam, Eric, Samra, Bachar, Baseri, Babak, Leaf, Andrea
• Format: Article
• Language: English
• Subjects: Cancer; Cancer therapies; Carboplatin; Case Report; Case reports; Chemotherapy; Clinical trials; Development and progression; Immunotherapy; Ipilimumab; Lung cancer; Lung cancer, Non-small cell; Lymphatic system; Metastasis; Monoclonal antibodies; Mutation; Patients; Pemetrexed; Radiotherapy; Targeted cancer therapy; Tumors; Worker absenteeism
• ISSN: 2090-6706; 2090-6714
• DOI: 10.1155/2019/1816472

Background. Exceptional responders to immune checkpoint inhibitors in metastatic non-small-cell lung cancer (NSCLC) are rare. Furthermore, the optimal duration of immunotherapy in patients who achieve complete remission and the benefit of rechallenge after recurrence remain unknown. Studying the clinical course of exceptional responders can help identify potential predictors of response to immunotherapy and further fine-tune our management algorithms in the absence of standard of care in challenging scenarios. Case Presentation. We highlight the case of a 73-year-old Vietnam War Veteran with active tobacco dependence who achieved complete response with nivolumab for metastatic NSCLC after four prior lines of chemotherapy. Nivolumab was discontinued after 10 cycles due to immune-mediated hepatitis that resolved with steroids. He remained in complete remission for 14 months while off therapy. Then, his tumor recurred twice locally in the mediastinum and he again achieved complete and durable responses after each recurrence with radiotherapy. Due to recurrence in both lungs one year later, he was rechallenged with nivolumab and achieved partial response after two months of therapy. He continues to do well five and a half years since his initial diagnosis of de novo metastatic NSCLC. Conclusion. Optimal management of exceptional responders to immune checkpoint inhibitors in metastatic NSCLC is largely unknown. Our case report adds to the limited data supporting the use of localized therapy for oligometastatic recurrences and rechallenge with immunotherapy for widespread disease in achieving disease control and long-term survival.